MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$933,032
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of conver...
Stock-based compensation
Other accrued expenses
Others
Negative Cash Flow Breakdown
Repayment of short-term note pay...
Operating lease liability
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Restricted cash
0
-
-
-
Net loss
-988,716
-1,300,949
-1,167,812
-1,323,629
Stock-based compensation
305,944
306,051
287,601
312,775
Non-cash operating lease expense
12,112
11,967
11,823
11,682
Depreciation
466
466
465
466
Prepaid expenses and other current assets
-24,533
-80,081
-87,609
-55,580
Accounts payable
116,657
99,095
-461,556
-133,263
Unearned grant revenue
-
-
0
0
Accrued interest
49,213
50,422
46,708
46,936
Other accrued expenses
133,316
406,932
337,094
200,929
Operating lease liability
-11,774
-11,630
-11,485
-11,343
Net cash used in operating activities
-358,249
-357,565
-869,553
-839,867
Proceeds from issuance of convertible notes payable
1,245,000
110,000
320,000
550,000
Proceeds from issuance of convertible notes payable - related parties
115,000
225,000
665,000
-20,000
Proceeds from issuance of common stock of majority-owned subsidiary
0
75,000
150,000
700,000
Repayment of short-term note payable
68,822
80,128
86,771
186,223
Net cash provided by financing activities
1,291,178
329,872
1,048,229
495,903
Effect of exchange rates on cash and restricted cash
103
285
136
-28
Net increase (decrease) in cash and restricted cash
933,032
-27,408
178,812
-343,992
Cash and restricted cash, beginning of period
223,883
251,291
72,479
489,726
Cash and restricted cash, end of period
1,156,915
223,883
251,291
72,479
Cash
1,156,915
-
251,291
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
convertible notes payable
$1,245,000
Proceeds from issuance of
convertible notes payable -...
$115,000
(-88.44%↓ Y/Y)
Net cash provided by
financing activities
$1,291,178
(-16.31%↓ Y/Y)
Effect of exchange
rates on cash and...
$103
(-76.70%↓ Y/Y)
Canceled cashflow
$68,822
Net increase
(decrease) in cash and...
$933,032
(1373.68%↑ Y/Y)
Canceled cashflow
$358,249
Repayment of short-term
note payable
$68,822
(145.24%↑ Y/Y)
Stock-based compensation
$305,944
(-51.98%↓ Y/Y)
Other accrued
expenses
$133,316
(-70.24%↓ Y/Y)
Accounts payable
$116,657
(-42.95%↓ Y/Y)
Accrued interest
$49,213
(-54.49%↓ Y/Y)
Prepaid expenses and
other current assets
-$24,533
(92.68%↑ Y/Y)
Non-cash operating lease
expense
$12,112
(-50.81%↓ Y/Y)
Depreciation
$466
(-50.00%↓ Y/Y)
Net cash used in
operating activities
-$358,249
(77.84%↑ Y/Y)
Canceled cashflow
$642,241
Net loss
-$988,716
(67.19%↑ Y/Y)
Operating lease liability
-$11,774
(53.46%↑ Y/Y)
Buy us a coffee
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)